MBTG easing into higher range...82/.84:
(COMTEX) B: Millennium Biotechnologies, Inc. Records A 33% Increase in Uni
B: Millennium Biotechnologies, Inc. Records A 33% Increase in Unit Sales For Q4,
BASKING RIDGE, N.J., Apr 14, 2004 (BUSINESS WIRE) -- Millennium
Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies
Group, Inc. (OTCBB:MBTG), announces a 33% increase in unit sales over the
preceding quarter.
Unit sales, in the fourth quarter, 2003 were 6,051 units compared to 4,555 units
for the third quarter, 2003, an increase of 33%. This, compares to sales of
1,901 units for the same period in 2002, representing 218% growth for Q4 2003
over Q4 2002. The increased sales are attributable to increased exposure in
communities served by Medicaid in New York state and ADAP, the state government
sponsored AIDS Drug Assistance Program. Additionally, significant awareness has
resulted from recent clinical trials that are currently being published as well
as other independent studies that are soon to be published. The results continue
to point out the efficacy of the Company's nutritional products on those
patients that suffer from immuno-compromising diseases, as an adjunct to their
medical care.
Millenium Biotechnologies, Inc. is a research-based nutraceutical Company and a
pioneer in the emerging field of specialized medical supplements. The Company
owns the patent to a unique nutritional supplement based on proprietary
technology and composition of nutritional base ingredients, nutraceuticals,
vitamins, amino acids and antioxidants, which have been developed over years of
research and study.
The Company's first two products, Resurgex(R) and ResurgexPlus(TM), are designed
to strengthen cellular defense and support the immune system in patients with
HIV/AIDS, Hepatitis C, cancer or other chronic illnesses. These products have
already qualified for Medicaid reimbursement in certain states, and the Company
plans to launch in other targeted locales upon further qualifications. For more
information about Millennium Biotechnologies, log onto www.milbiotech.com.
Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium
Biotechnologies, Group, Inc. is a research-based nutraceutical company and a
pioneer in the emerging field of specialized enteral nutritional formulas and
nutraceuticals. The company's first two products, Resurgex(R) and Resurgex
Plus(TM), are the first multiple action nutritional formulas designed to assist
in increasing energy, maintaining lean muscle, reducing oxidative stress and
supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or
other chronic illnesses as an adjunct to their medical care. Both Resurgex(R)
and Resurgex Plus(TM), contain the critically important, orally effective form
of SOD (DefenZyme(TM)) along with several other important nutritional
components. These products are being reimbursed by Medicaid in certain states,
and the company plans to launch in other targeted locales upon further
qualifications. For more information about Millennium Biotechnologies, Inc., log
onto www.milbiotech.com.
This news release contains forward-looking statements that are based upon
management's beliefs as well as on assumptions made by and data currently
available to management. This information which has been, or in the future may
be, included in reliance on the "safe harbor" provisions on the Private
Securities Litigation Reform Act of 1995, is subject to a number of risks and
uncertainties, including but not limited to uncertainty as to market acceptance
of Resurgex(R), Resurgex Plus(TM) and Defenzyme(TM) and the factors identified
in the Company's 10-KSB and other documents filed with the Securities and
Exchange Commission. Actual results may differ materially from those anticipated
in such forward-looking statements even if experience or future changes make it
clear that any projected results expressed or implied therein may not be
realized. The Company undertakes no obligation to update or revise any
forward-looking statements to reflect subsequent events or circumstances.
SOURCE: Millennium Biotechnologies, Inc.
CONTACT: Millennium Biotechnologies, Inc.
Jerry Swon, 908-604-2500
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
-0-
KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
*** end of story *** |
